31.49 USD
▲-0.18+6.24%
盘后 29.41 -0.78%
2026-08-03
市值
$1.47B
市盈率
—
EPS
-3.52
股息率
—
52 周区间
16.10 – 35.83
成交量
427.47K
Beta
1.30
目标价
44.60
52W 低 16.1052W 高 35.83
价格走势
公司简介
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC...